Format

Send to

Choose Destination
Vaccine. 2015 Jun 26;33(29):3314-21. doi: 10.1016/j.vaccine.2015.05.038. Epub 2015 May 28.

Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses.

Author information

1
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
2
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Faculty of Life Sciences, University of Vienna, Vienna, Austria.
3
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
4
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: florian.krammer@mssm.edu.

Abstract

Current influenza virus vaccines provide solid protection from infection with viruses that are well matched with the vaccine strains. However, they do not protect efficiently against drifted or shifted strains. We developed an antigen based on the conserved stalk domain of the influenza virus hemagglutinin and tested its efficacy as a vaccine in a mouse virus challenge model. Although the antigen lacked the correct conformation of the native stalk domain and was not recognized by a panel of neutralizing stalk-reactive antibodies, it did induce considerable protection against H1N1, H5N1 and H6N1 challenge strains. Protection was enhanced when mice had pre-existing immunity against the stalk domain. Since pre-existing immunity is also present in the human population, we hypothesize that a similar antigen could show efficacy in humans as well.

KEYWORDS:

HA stalk; Headless hemagglutinin; Heterosubtypic immunity; Influenza virus; Universal influenza virus vaccine

PMID:
26026378
PMCID:
PMC4472732
DOI:
10.1016/j.vaccine.2015.05.038
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center